New cataract surgery combination gel impressive

Article

A chloramphenicol 0.25%-betamethasone 0.13% (C&B) gel combination has comparable efficacy and tolerance and better acceptance by patients than an aqueous tobramycin 0.3%-dexamethasone 0.1% (T&D) preparation for controlling inflammation and prophylaxis of endophthalmitis following cataract surgery.

A chloramphenicol 0.25%-betamethasone 0.13% (C&B) gel combination has comparable efficacy and tolerance and better acceptance by patients than an aqueous tobramycin 0.3%-dexamethasone 0.1% (T&D) preparation for controlling inflammation and prophylaxis of endophthalmitis following cataract surgery, according to the results of a study published in the September/October issue of the European Journal of Ophthalmology.

Fabrizio Camesasca and colleagues from the Italian Betamethasone-Chloramphenicol versus Dexamethasone-Tobramycin Combination study group conducted a prospective, randomized clinical trial of patients with bilateral operative cataract. Postoperatively, for 15 days, one eye was randomly assigned to therapy with the C&B combination three times a day (Group 1) and the other to the T&D combination eye-drops four times a day.

A total of 142 patients (284 eyes) completed the study. The two groups were comparable with regards efficacy, side effects, uncorrected visual acuity, intraocular pressure, oedema or hyperemia of the eyelids, decreased corneal transparency, corneal oedema, Descemet folds, anterior chamber Tyndall and depth and posterior synechiae. Postoperative subjective pain and dry eye sensation were also comparable but the C&B gel combination elicited a significantly more pleasant sensation in patients (p=0.04).

The authors believe that the superior patient acceptance of the C&B gel combination will improve patient compliance and therefore help decrease potential side effects from cataract surgery.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Recent Videos
Jay Chhablani, MD, shares late-breaking data from the ArMaDa trial, investigating gene therapy for Geographic Atrophy and dry age-related macular degeneration, at EURETINA
Editorial advisory board member Alexandra Miere, MD, PhD, speaks about the ACTOR and HERMES studies at the 2025 European Society of Retina Specialists (EURETINA) Congress
María Berrocal, MD, speaks about the Vit-Buckle Society symposium hosted at the 2025 European Society of Retina Specialists (EURETINA) annual meeting
© 2025 MJH Life Sciences

All rights reserved.